Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy

The purpose of this study is to determine the safety and effectiveness of TAK-583, once daily (QD), in the treatment of neuropathy caused by diabetes mellitus.

Study Overview

• Status: Completed
• Conditions: Diabetic Neuropathies
• Intervention / Treatment: Drug: TAK-583; Drug: TAK-583; Drug: TAK-583; Drug: Placebo

Detailed Description

Diabetic polyneuropathy is a frequent complication in individuals with type 1 and 2 diabetes mellitus, and can result in progressive functional and structural deficits in both somatic and autonomic nerves. Diabetic polyneuropathy is characterized by degenerative changes in nerve fibers resulting in progressive functional and structural deficits in both somatic and autonomic nerves.

TAK-583 is a synthetic compound currently under development for the treatment of diabetic polyneuropathy. The purpose of this study is to evaluate the safety and efficacy of TAK-583 for the treatment of mild to moderate diabetic polyneuropathy in subjects with type 1 or type 2 diabetes mellitus. Study participation is anticipated to be about 8 months.

• Study Type: Interventional
• Enrollment (Actual): 338
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada
  • Ontario
    • Kingston, Ontario, Canada
    • North Bay, Ontario, Canada
  • Quebec
    • Laval, Quebec, Canada
    • Quebec City, Quebec, Canada
• United States
  • Arizona
    • Mesa, Arizona, United States
    • Peoria, Arizona, United States
    • Phoenix, Arizona, United States
    • Tucson, Arizona, United States
  • Arkansas
    • Jonesboro, Arkansas, United States
  • California
    • Huntington Beach, California, United States
    • La Jolla, California, United States
    • Los Angeles, California, United States
    • Pasadena, California, United States
    • Tustin, California, United States
  • Florida
    • Largo, Florida, United States
    • Miami, Florida, United States
    • New Port Richey, Florida, United States
    • Palm Beach Gardens, Florida, United States
    • Sunrise, Florida, United States
    • West Palm Beach, Florida, United States
  • Georgia
    • Decatur, Georgia, United States
  • Idaho
    • Idaho Falls, Idaho, United States
  • Illinois
    • Chicago, Illinois, United States
  • Massachusetts
    • Boston, Massachusetts, United States
  • Michigan
    • Ann Arbor, Michigan, United States
  • Nevada
    • Las Vegas, Nevada, United States
  • New Jersey
    • Englewood, New Jersey, United States
  • New York
    • Buffalo, New York, United States
    • Staten Island, New York, United States
  • North Carolina
    • Greenville, North Carolina, United States
  • Ohio
    • Cleveland, Ohio, United States
  • Oregon
    • Portland, Oregon, United States
  • Pennsylvania
    • Duncansville, Pennsylvania, United States
  • Texas
    • Dallas, Texas, United States
    • Houston, Texas, United States
    • San Antonio, Texas, United States
  • Virginia
    • Norfolk, Virginia, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Female subjects must be post-menopausal or status post documented hysterectomy and bilateral oophorectomy.
• Has fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed not clinically significant by the investigator prior to randomization.
• Has Type 1 or type 2 diabetes, as defined by World Health Organization Criteria.

• Has mild to Moderate Diabetic Peripheral Neuropathy defined as:

  • Confirmed abnormality of at least two nerve conduction velocity parameters as defined by the Neurological Core Laboratory.
  • Sural sensory nerve potential amplitude greater than or equal to 1 μV (microvolt).
• Has glycosylated hemoglobin less than or equal to 10%.
• Is on stable pain medications for at least 3 weeks prior to randomization, if applicable.
• Has a glomerular filtration rate calculated by Modification of Diet in Renal Disease of greater than or equal to 45 mL/min/ body surface area.
• Spot albumin/creatinine ratio of less than 300 mg/g creatinine or 33.9 mg/mmol creatinine.

• Has acceptable clinical laboratory test results as defined by:

  • Hemoglobin Greater than or equal to 9.0 g/dL or 5.58 mmol/L
  • Thyroid stimulating hormone Within normal limits
  • Free T4 index Within normal limits
  • B12 level Within normal limits
• Is willing to follow an American Diabetes Association or similar recommended dietary regimen.

Exclusion Criteria

• Individuals with a history of other neuropathies due to causes other than diabetes such as alcohol abuse, liver or renal disease, uremia, toxic exposure, genetic factors, autoimmune disorders, inflammatory demyelinating diseases, monoclonal gammopathies; or endocrine, metabolic or nutritional disorders.
• Has clinical or electrophysiologic evidence of bilateral carpal tunnel syndrome.
• Has a significant skin abnormality or ulcerative changes in their lower extremities that may interfere with the performance of the study related procedures.
• Has a body mass index greater than 45 kg/m2.
• Participants with uncontrolled hypertension or a systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure of greater than 95 mm Hg.
• Has a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, clinically significant abnormal electrocardiograms, New York Heart Association Functional Classification III or IV, or documented cerebrovascular accident.
• Has a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval greater than 450 milliseconds).
• Has a history of additional risk factors for Torsades de pointes.

• Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

  • Medications that prolong the QT/QTc interval.
  • Lipoic acid.
  • Linolenic acid (primrose oil).
  • Inositol.
  • Topiramate.
  • Acetyl-L-Carnitine.
  • Nerve growth factors.
  • Capsaicin.
  • CYP3A4 inhibitors (amiodarone, diltiazem, Verapamil)
  • HIV protease inhibitors
  • Itraconazole
  • Ketoconazole
  • macrolide antibiotics
  • CYP 3A4 inducers
• Has an alanine aminotransferase level of greater than 1.5 times upper limit of normal, active liver disease or jaundice or Total bilirubin greater than 1.2 times upper limit of normal.
• Has a 12-hour urinary cortisol test greater than 264 nmol/night (95.6 mcg/night) at screening.
• Has clinically significant (as determined by the investigator) or unstable: pulmonary, gastrointestinal, hepatic, hematologic, musculoskeletal, osteoporosis, osteopenia, or endocrine (other than diabetes mellitus or stably treated hypothyroidism) diseases.
• Has a previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.
• Has any other serious disease or condition at screening or at randomization that might affect life expectancy or make it difficult to successfully manage and follow the subjects according to the protocol.
• Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
• Has a known hypersensitivity to a compound related to TAK-583.
• Is currently participating in another investigational study or has participated in an investigational study within the past 30 days.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: TAK-583 5 mg QD	Drug: TAK-583; TAK-583 5 mg, tablets, orally, once daily for up to 6 months.; Drug: TAK-583; TAK-583 50 mg, tablets, orally, once daily for up to 6 months.; Drug: TAK-583; TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
EXPERIMENTAL: TAK-583 50 mg QD	Drug: TAK-583; TAK-583 5 mg, tablets, orally, once daily for up to 6 months.; Drug: TAK-583; TAK-583 50 mg, tablets, orally, once daily for up to 6 months.; Drug: TAK-583; TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
EXPERIMENTAL: TAK-583 100 mg QD	Drug: TAK-583; TAK-583 5 mg, tablets, orally, once daily for up to 6 months.; Drug: TAK-583; TAK-583 50 mg, tablets, orally, once daily for up to 6 months.; Drug: TAK-583; TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
PLACEBO_COMPARATOR: Placebo QD	Drug: Placebo; TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change from Baseline for a composite measure of Maximal Nerve Conduction Velocity of the Peroneal and Median Motor Nerves and the Median and Sural Sensory Nerves.	Month 6 or Final Visit

Secondary Outcome Measures

Outcome Measure	Time Frame
Change from Baseline in Electrophysiological Parameters for Individual Nerves.	Month 6 or Final Visit
Change from Baseline in Sensory Sub-Composite and Motor Sub-Composite Scores.	Months 3 and 6 or Final Visit
Change in Vibration Perception Threshold.	Months 3 and 6 or Final Visit
Change in Pain Scores.	Months 1, 2, 3, 4, 5, and 6 or Final Visit
Change in Neurological Examination Score.	Months 3 and 6 or Final Visit
Change in Quality of Life Index Score.	Months 1, 2, 3, 4, 5, and 6 or Final Visit
Change in glycosylated hemoglobin.	Months 3 and 6 or Final Visit
Change in fasting plasma glucose.	Months 3 and 6 or Final Visit
Change in fasting insulin.	Months 3 and 6 or Final Visit
Change in Fasting C-peptide.	Months 3 and 6 or Final Visit

Collaborators and Investigators

• Sponsor: Takeda

Study record dates

Study Major Dates

• Study Start: September 1, 2006
• Primary Completion (ACTUAL): February 1, 2008
• Study Completion (ACTUAL): February 1, 2008

Study Registration Dates

• First Submitted: September 24, 2008
• First Submitted That Met QC Criteria: September 25, 2008
• First Posted (ESTIMATE): September 26, 2008

Study Record Updates

• Last Update Posted (ESTIMATE): June 22, 2016
• Last Update Submitted That Met QC Criteria: June 20, 2016
• Last Verified: June 1, 2016

More Information

Terms related to this study

• Keywords: Drug Therapy; Diabetic Polyneuropathy; Diabetic Autonomic Neuropathy; Asymmetric Diabetic Proximal Motor Neuropathy; Neuralgia, Diabetic; Diabetic Amyotrophy; Symmetric Diabetic Proximal Motor Neuropathy
• Additional Relevant MeSH Terms: Nervous System Diseases; Endocrine System Diseases; Diabetes Complications; Diabetes Mellitus; Neuromuscular Diseases; Peripheral Nervous System Diseases; Diabetic Neuropathies
• Other Study ID Numbers: 01-06-TL-583-006; U1111-1129-7781 (REGISTRY: WHO)